Search

everythinglearnresearchcommunity

for

Search:↓

About 7% to 15% of Iranian women have polycystic ovary syndrome, depending on the criteria used to diagnose it.

Women with PCOS have heart-related issues not because of obesity, but due to insulin resistance and low adiponectin levels.

Pregnancy can cause skin darkening, varicose veins, more sweating, hair growth, hair loss after birth, nail changes, and gum inflammation.

Cepharanthine is a well-tolerated drug with multiple medical uses, including anti-inflammatory and anti-cancer properties.

Lignans and neolignans from plants may help protect against various health issues, including cancer and heart disease.

Hormonal treatments can help with acne, especially in women, by lowering androgen levels or blocking their effects.

Insulin resistance may contribute to various skin diseases and treating it could improve skin health and prevent more serious conditions.

Women with PCOS have different levels of certain fats and proteins in their blood, which could help diagnose the condition.

PCOS symptoms change with age; younger women have higher androgen levels and less metabolic issues, while older women face more metabolic challenges despite milder PCOS symptoms.

Pregnant women often experience skin and hair changes, with over half getting stretch marks and pigment changes, and should be cautious with cosmetic procedures due to potential risks.

Endocrine therapies for cancer significantly increase the risk of hair loss.

Obese women with PCOS are more likely to have fatty liver disease.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

More PDCD4 is linked to obesity, insulin problems, and cell death in ovaries for those with polycystic ovary syndrome.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

Low prolactin in young women may increase heart and metabolism risks.

Testosterone therapy seems safe and effective for transgender men with proper care, but more long-term research is needed.

The document concludes that diagnosing and treating Congenital Adrenal Hyperplasia is complex and requires a team approach due to its effects on the skin and other symptoms.

Birth control pills combined with bicalutamide are more effective at reducing excessive hair growth in women with PCOS than birth control pills alone.

Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.

New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.

Irregular menstrual cycles in teenagers are linked to a higher risk of polycystic ovary syndrome and metabolic syndrome.

Proper skin toxicity management in chemotherapy is key to continuing treatment and keeping patient quality of life high.

L-cystine and vitamin B6 at high doses prevented hair loss in mice treated with a chemotherapy drug.

Cyproterone acetate is the preferred treatment for women's hyperandrogenism when estrogen/progestogen use is safe.

Birth control pills containing cyproterone acetate improve the quality of life more for women with polycystic ovary syndrome after 6 months of use.

The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.

The hairless gene is crucial for hair health, and its mutations cause hair loss.

PCOS symptoms vary by age, affecting diagnosis and treatment.

Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.